We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+4.18%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$13.8M
Cap. Flow
+$18M
Cap. Flow %
5.13%
Top 10 Hldgs %
37.4%
Holding
88
New
31
Increased
19
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$9.29M
2
DHR icon
Danaher
DHR
+$9.16M
3
ZBH icon
Zimmer Biomet
ZBH
+$8.78M
4
NTLA icon
Intellia Therapeutics
NTLA
+$7.38M
5
MRK icon
Merck
MRK
+$6.96M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$8.76M
2
LLY icon
Eli Lilly
LLY
+$8.44M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.37M
4
NVRO
NEVRO CORP.
NVRO
+$7.83M
5
ABBV icon
AbbVie
ABBV
+$7.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.97%
2 Energy 3%
3 Industrials 0.97%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$84.7B
$5.38M 1.54%
15,000
-13,000
-46% -$4.18M
TFX icon
27
Teleflex
TFX
$5.91B
$4.99M 1.42%
+12,000
New +$4.8M
BDX icon
28
Becton Dickinson
BDX
$49.4B
$4.86M 1.39%
20,500
-12,300
-38% -$3.01M
PTCT icon
29
PTC Therapeutics
PTCT
$6.15B
$4.74M 1.35%
100,100
+70,000
+233% +$4.16M
SGFY
30
DELISTED
Signify Health, Inc.
SGFY
$4.68M 1.34%
+160,000
New +$4.95M
GMED icon
31
Globus Medical
GMED
$11.4B
$4.63M 1.32%
75,000
+25,000
+50% +$1.58M
EXEL icon
32
Exelixis
EXEL
$12.7B
$4.52M 1.29%
+200,000
New +$4.52M
RETA
33
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4.39M 1.25%
44,000
-6,000
-12% -$700K
NSTG
34
DELISTED
NanoString Technologies, Inc.
NSTG
$4.27M 1.22%
+65,000
New +$4.56M
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.64B
$4.07M 1.16%
+400,000
New +$4.12M
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$13.5B
$3.93M 1.12%
52,000
-33,000
-39% -$2.7M
HZNP
37
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.68M 1.05%
+40,000
New +$3.38M
PNTG icon
38
Pennant Group
PNTG
$1.33B
$3.66M 1.05%
80,000
+20,000
+33% +$1.1M
NTRA icon
39
Natera
NTRA
$45.1B
$3.55M 1.02%
35,000
-10,000
-22% -$1.1M
ACCD
40
DELISTED
Accolade Inc
ACCD
$3.4M 0.97%
+75,000
New +$3.61M
FATE icon
41
Fate Therapeutics
FATE
$319M
$3.3M 0.94%
+40,000
New +$3.83M
BMY icon
42
Bristol-Myers Squibb
BMY
$130B
$3.16M 0.9%
+50,000
New +$3.11M
AMRN
43
Amarin Corp
AMRN
$296M
$3.1M 0.89%
+25,000
New +$3.36M
VRTX icon
44
Vertex Pharmaceuticals
VRTX
$134B
$3.01M 0.86%
+14,000
New +$3.08M
PODD icon
45
Insulet
PODD
$10B
$2.61M 0.75%
+10,000
New +$2.68M
THC icon
46
Tenet Healthcare
THC
$20.9B
$2.6M 0.74%
+50,000
New +$2.53M
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$2.47M 0.7%
85,000
– –
AXNX
48
DELISTED
Axonics, Inc. Common Stock
AXNX
$2.4M 0.68%
+40,000
New +$2.17M
INSM icon
49
Insmed
INSM
$29B
$2.38M 0.68%
70,000
+20,000
+40% +$764K
AGIO icon
50
Agios Pharmaceuticals
AGIO
$1.95B
$2.22M 0.63%
43,000
-32,000
-43% -$1.58M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Integral Health Asset Management held 88 positions worth $350M, up 4.1% from $336M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Integral Health Asset Management deployed $18M of net new capital in Q1 2021, opening 31 new positions and adding to 19 existing holdings. Its largest new stake was Centene: 150,000 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was NEVRO CORP., an estimated $7.83M trimmed.

  • Integral Health Asset Management's largest Q1 2021 buy was Centene: 150,000 shares worth $9.59M.
  • Integral Health Asset Management added most to Intellia Therapeutics in Q1 2021, an estimated $7.38M increase.
  • Integral Health Asset Management's biggest Q1 2021 reduction was NEVRO CORP., cutting an estimated $7.83M.
  • Integral Health Asset Management fully exited Abbott in Q1 2021, selling an estimated $8.76M.
  • Integral Health Asset Management's ten largest holdings make up 37% of its $350M portfolio in Q1 2021.
  • Integral Health Asset Management opened 31 new positions and closed 19 in Q1 2021.
  • Integral Health Asset Management's portfolio value rose 4.1% quarter-over-quarter to $350M.

Based on Integral Health Asset Management's 13F filing for Q1 2021, filed 10 May 2021.